Columvi

Relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy in adults.

IV Pre-treatment w/ obinutuzumab: Obinutuzumab 1,000 mg on cycle 1 day 1 (7 days prior to Columvi initiation) as infusion at 50 mg/hr. May be escalated in 50 mg/hr increments every 30 mins to max of 400 mg/hr. Columvi dose step-up schedule: 2.5 mg on cycle 1 day 8 in 4 hr infusion duration. 10 mg on cycle 1 day 15 in 4 hr infusion duration. 30 mg on cycle 2 day 1 in 4 hr infusion duration. 30 mg on cycle 3-12 day 1 in 2 hr infusion duration. Each cycle is 21 days. Max treatment duration: 12 cycles or until disease progression or unmanageable toxicity occurs 1st.

Hypersensitivity.

Targeted Cancer Therapy

L01FX28 - glofitamab ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.

POM